Ambry Genetics introduces a suite of genetic tests to pinpoint the cause of mental retardation

Ambry Genetics today introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).  This panel marks the first time next generation sequencing technology, coupled with microarrays, Sanger sequencing and traditional Fragile X testing, is being made clinically available to address this disorder, giving physicians a full range of reflex options to suit the needs of their patients.

The Ambry XLMR SuperPANEL spans all levels of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of approximately ninety specific target genes.  Components include the XLMR Array Plus™, the XLMR Next Gen Sequencing Panel, and individual sequencing tests including Fragile X.  Testing can be customized for individual patients.  The Sequencing Panel uses new and innovative technologies, including RainDance Technologies' RDT 1000 system for sequence enrichment with the Illumina Genome Analyzer IIx.  Ambry has been an Illumina Certified Service Provider for research services since 2007.

"I'm very excited about the various technologies we applied to this suite of tests, and that we can develop similar tests for other complex disease states," said Anja Kammesheidt, Chief Scientific Officer at Ambry Genetics. "The new technologies create an important paradigm shift and allow us to comprehensively investigate complex genetic disorders in the same way monogenic disorders have been diagnosed for years."

"Ambry Genetics is ideally suited to bring multigenic assays into the marketplace," said Charles Dunlop, Chief Executive Officer.  "We've not only been performing services on these platforms for years with a very good understanding of the nuances of these technologies, but we also have over a decade of experience launching high information-content sequencing tests.  We know how to deal with the interpretation issues that arise at the patient level, and our company is geared towards helping physicians with this type of information."